Статті в журналах з теми "Drug repurposing against Aurora-kinases"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Drug repurposing against Aurora-kinases".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Islam, Saiful, Theodosia Teo, Malika Kumarasiri, Martin Slater, Jennifer H. Martin, Shudong Wang, and Richard Head. "Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells." Pharmaceuticals 15, no. 10 (September 25, 2022): 1186. http://dx.doi.org/10.3390/ph15101186.
Повний текст джерелаPereira Moreira, Bernardo, Michael H. W. Weber, Simone Haeberlein, Annika S. Mokosch, Bernhard Spengler, Christoph G. Grevelding, and Franco H. Falcone. "Drug Repurposing and De Novo Drug Discovery of Protein Kinase Inhibitors as New Drugs against Schistosomiasis." Molecules 27, no. 4 (February 19, 2022): 1414. http://dx.doi.org/10.3390/molecules27041414.
Повний текст джерелаPatel, Gautam, Norma E. Roncal, Patricia J. Lee, Susan E. Leed, Jessey Erath, Ana Rodriguez, Richard J. Sciotti, and Michael P. Pollastri. "Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery." Med. Chem. Commun. 5, no. 5 (2014): 655–58. http://dx.doi.org/10.1039/c4md00045e.
Повний текст джерелаRegan-Fendt, Kelly, Ding Li, Ryan Reyes, Lianbo Yu, Nissar A. Wani, Peng Hu, Samson T. Jacob, Kalpana Ghoshal, Philip R. O. Payne, and Tasneem Motiwala. "Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma." Cancers 12, no. 10 (September 23, 2020): 2730. http://dx.doi.org/10.3390/cancers12102730.
Повний текст джерелаFerrarelli, Leslie K. "Repurposing an HIV drug for melanoma." Science Signaling 9, no. 423 (April 12, 2016): ec85-ec85. http://dx.doi.org/10.1126/scisignal.aaf8440.
Повний текст джерелаYu, Ga-Ram, Seung-Jun Lee, Dong-Woo Lim, Hyuck Kim, Jai-Eun Kim, and Won-Hwan Park. "Drug Repurposing in Alternative Medicine: Sochehwan, a Polyherbal Traditional Korean Digestant, Protects against Alcoholic Steatohepatitis by Regulating Cytochrome P450 2E1 Expression." Processes 9, no. 10 (September 30, 2021): 1760. http://dx.doi.org/10.3390/pr9101760.
Повний текст джерелаThirunavukkarasu, Muthu Kumar, Utid Suriya, Thanyada Rungrotmongkol, and Ramanathan Karuppasamy. "In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach." Pharmaceutics 14, no. 1 (December 28, 2021): 59. http://dx.doi.org/10.3390/pharmaceutics14010059.
Повний текст джерелаHan, Hyun-Ju, та Chang-Gu Hyun. "Acenocoumarol Exerts Anti-Inflammatory Activity via the Suppression of NF-κB and MAPK Pathways in RAW 264.7 Cells". Molecules 28, № 5 (22 лютого 2023): 2075. http://dx.doi.org/10.3390/molecules28052075.
Повний текст джерелаR. Sahrawat, Tammanna, and Prabhjeet Kaur Kaur. "Polypharmacological study of Ceritinib using a structure based in silico approach." Bionatura 4, no. 2 (May 15, 2019): 836–40. http://dx.doi.org/10.21931/rb/2019.04.02.3.
Повний текст джерелаBrunotte, Linda, Shuyu Zheng, Angeles Mecate-Zambrano, Jing Tang, Stephan Ludwig, Ursula Rescher, and Sebastian Schloer. "Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro." Pharmaceutics 13, no. 9 (September 3, 2021): 1400. http://dx.doi.org/10.3390/pharmaceutics13091400.
Повний текст джерелаElkamhawy, Ahmed, Usama M. Ammar, Sora Paik, Magda H. Abdellattif, Mohamed H. Elsherbeny, Kyeong Lee, and Eun Joo Roh. "Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening." Molecules 26, no. 17 (September 1, 2021): 5324. http://dx.doi.org/10.3390/molecules26175324.
Повний текст джерелаMeijer, Laurent, Deborah J. Nelson, Vladimir Riazanski, Aida G. Gabdoulkhakova, Geneviève Hery-Arnaud, Rozenn Le Berre, Nadège Loaëc, et al. "Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis." Journal of Innate Immunity 8, no. 4 (2016): 330–49. http://dx.doi.org/10.1159/000444256.
Повний текст джерелаMaxson, Julia Elizabeth, Abel L. Melissa, Jinhua Wang, Xianming Deng, Samuel B. Luty, Huahang Sun, Julie Gorenstein, et al. "Development and Repurposing of Small-Molecule Kinase Inhibitors to Target Novel Leukemogenic TNK2 Mutations." Blood 124, no. 21 (December 6, 2014): 435. http://dx.doi.org/10.1182/blood.v124.21.435.435.
Повний текст джерелаChen, Ya-Ping, Hui-Ju Lin, Kung-Chao Chang, Jiann-Shiuh Chen, Ming-Ying Tsai, Liang-Yi Hung, and Tsai-Yun Chen. "Targeting Aurora Kinases in Acute Lymphoblastic Leukemia." Blood 120, no. 21 (November 16, 2012): 4907. http://dx.doi.org/10.1182/blood.v120.21.4907.4907.
Повний текст джерелаManey, N., H. De Paula-Lemos, B. Barron-Millar, A. Mellor, J. D. Isaacs, A. Anderson, and A. Pratt. "SAT0013 PIM-1 KINASE IS A MEASURABLE MEDIATOR OF CD4+ T CELL DYSREGULATION AND THERAPEUTIC TARGET IN EARLY RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 936.1–937. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2818.
Повний текст джерелаMoore, Andrew S., Amir Faisal, Vassilios Bavetsias, Chongbo Sun, Butrus Atrash, Melanie Valenti, Alexis de Haven Brandon, et al. "Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo." Blood 116, no. 21 (November 19, 2010): 3289. http://dx.doi.org/10.1182/blood.v116.21.3289.3289.
Повний текст джерелаReiman, Tony, Robert P. Evans, Claudia Naber, Tara Steffler, Jonathan J. Keats, Troy Perry, Christopher A. Maxwell, Heidi Chau, Andrew R. Belch, and Linda M. Pilarski. "Aurora Kinases as Therapeutic Targets in Multiple Myeloma." Blood 108, no. 11 (November 16, 2006): 847. http://dx.doi.org/10.1182/blood.v108.11.847.847.
Повний текст джерелаBesse, Lenka, Andrej Besse, Marianne Kraus, Matej Jasik, Ondrej Slaby, and Christoph Driessen. "Abstract 2851: ALK-inhibitors as a novel potential therapy for proteasome inhibitor-resistant multiple myeloma." Cancer Research 83, no. 7_Supplement (April 4, 2023): 2851. http://dx.doi.org/10.1158/1538-7445.am2023-2851.
Повний текст джерелаPollard, John R., Peter A. Charlton, Graham M. T. Cheetham, Susanna C. Falcon, Julian M. C. Golec, Matthew R. Griffiths, and Peter Weber. "Structural Basis and Cellular Consequences of Potent Inhibition of the Aurora Kinases, Wild Type Abl Kinase and a T315I Multi-Drug Resistant Mutant Form of Abl Kinase by MK-0457 (VX-680)." Blood 108, no. 11 (November 16, 2006): 1368. http://dx.doi.org/10.1182/blood.v108.11.1368.1368.
Повний текст джерелаKaratas, Mehmet, Apirat Chaikuad, Bianca Berger, Michael H. G. Kubbutat, Frank Totzke, Stefan Knapp, and Conrad Kunick. "7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones Designed by a “Cut and Glue” Strategy Are Dual Aurora A/VEGF-R Kinase Inhibitors." Molecules 26, no. 6 (March 14, 2021): 1611. http://dx.doi.org/10.3390/molecules26061611.
Повний текст джерелаOkabe, Seiichi, Tetsuzo Tauchi, Seiichiro Katagiri, Yuko Tanaka, and Kazuma Ohyashiki. "Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells." Blood 120, no. 21 (November 16, 2012): 1333. http://dx.doi.org/10.1182/blood.v120.21.1333.1333.
Повний текст джерелаCheung, Kam, Gloria Juan, William Wayne, Kelly Hanestad, Kathleen Keegan, Justin Huard, Patricia McElroy, et al. "AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo." Blood 122, no. 21 (November 15, 2013): 3823. http://dx.doi.org/10.1182/blood.v122.21.3823.3823.
Повний текст джерелаIslam, Saiful, Muhammed H. Rahaman, Mingfeng Yu, Benjamin Noll, Jennifer H. Martin, Shudong Wang, and Richard Head. "Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition." Cancers 15, no. 4 (February 7, 2023): 1044. http://dx.doi.org/10.3390/cancers15041044.
Повний текст джерелаLunghi, Paolo, Laura Mazzera, Guerino Lombardi, Micaela Ricca, Manuela Abeltino, Davide Arienti, Anna Maria Cantoni, Attilio Corradi, and Antonio Bonati. "Pan-Aurora Kinases and TRAIL Combination Therapy Has Potent Antitumor Activity In Vivo Against Drug-Resistant Human Multiple Myeloma Xenograft Model." Blood 118, no. 21 (November 18, 2011): 1846. http://dx.doi.org/10.1182/blood.v118.21.1846.1846.
Повний текст джерелаAbdusalam, Ashraf Ahmed Ali. "In-silico identification of novel inhibitors for human Aurora kinase B form the ZINC database using molecular docking-based virtual screening." Research Results in Pharmacology 8, no. 4 (December 15, 2022): 89–99. http://dx.doi.org/10.3897/rrpharmacology.8.82977.
Повний текст джерелаBhongade, Bhoomendra A., Nikhil D. Amnerkar, and Andanappa K. Gadad. "3D-QSAR Studies on 4,5-Dihydro-1H-pyrazolo [4,3-h] Quinazolines as Plk-1, CDK2/A and Aur-A Serine/Threonine Kinase Inhibitors." Letters in Drug Design & Discovery 17, no. 4 (April 25, 2020): 388–95. http://dx.doi.org/10.2174/1570180816666190611161332.
Повний текст джерелаGou, Xuxu, Beom-Jun Kim, Meenakshi Anurag, Jonathan T. Lei, Meggie N. Young, Matthew V. Holt, Diana Fandino, et al. "Abstract 5011: Targeting kinome reprogramming in ESR1 fusion-driven breast cancer." Cancer Research 83, no. 7_Supplement (April 4, 2023): 5011. http://dx.doi.org/10.1158/1538-7445.am2023-5011.
Повний текст джерелаBehera, Ranjan, Sarah M. Thomas, and Kojo Mensa-Wilmot. "New Chemical Scaffolds for Human African Trypanosomiasis Lead Discovery from a Screen of Tyrosine Kinase Inhibitor Drugs." Antimicrobial Agents and Chemotherapy 58, no. 4 (January 27, 2014): 2202–10. http://dx.doi.org/10.1128/aac.01691-13.
Повний текст джерелаHargrave, Darren R., Andrew DJ Pearson, Lucas Moreno, Bruce Morland, Martin Elliott, Guy Makin, Quentin Campbell-Hewson, et al. "A phase I trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refractory solid tumours." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 9542. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9542.
Повний текст джерелаPodesta, Jennifer E., Melanie J. Griffin, Richard Sugar, Matthew S. Squires, Alan Boddy, Spiros Linardopoulos, Andrew DJ Pearson, and Andrew S. Moore. "Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 Kinases by AT9283 In Children and Adolescents with Leukaemia." Blood 116, no. 21 (November 19, 2010): 1818. http://dx.doi.org/10.1182/blood.v116.21.1818.1818.
Повний текст джерелаLee, Kyeong, Hossam Nada, Hyun Jung Byun, Chang Hoon Lee, and Ahmed Elkamhawy. "Hit Identification of a Novel Quinazoline Sulfonamide as a Promising EphB3 Inhibitor: Design, Virtual Combinatorial Library, Synthesis, Biological Evaluation, and Docking Simulation Studies." Pharmaceuticals 14, no. 12 (November 30, 2021): 1247. http://dx.doi.org/10.3390/ph14121247.
Повний текст джерелаMoore, Andrew S., Amir Faisal, Vassilios Bavetsias, David Gonzalez de Castro, Chongbo Sun, Butrus Atrash, Melanie Valenti, et al. "Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736,." Blood 118, no. 21 (November 18, 2011): 3492. http://dx.doi.org/10.1182/blood.v118.21.3492.3492.
Повний текст джерелаPanicker, Resmi C., Anthony G. Coyne, and Rajavel Srinivasan. "Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?" Current Medicinal Chemistry 26, no. 13 (July 8, 2019): 2234–42. http://dx.doi.org/10.2174/0929867324666170727120315.
Повний текст джерелаHembrough, Todd A., Xiaoru Chen, Patricia A. Burke, Glenn M. Swartz, Kathleen Bengali, Richard Brokx, Theresa M. LaVallee, and Mark R. Bray. "Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693." Blood 110, no. 11 (November 16, 2007): 1209. http://dx.doi.org/10.1182/blood.v110.11.1209.1209.
Повний текст джерелаLotfi, Shamim, Aarthi Jayanthan, Victor A. Lewis, Greg Guilcher, Matthew S. Squires, Todd Cooper, and Aru Narendran. "AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells." Blood 114, no. 22 (November 20, 2009): 3078. http://dx.doi.org/10.1182/blood.v114.22.3078.3078.
Повний текст джерелаSanto, Loredana, Teru Hideshima, Diana Cirstea, Madhavi L. Bandi, Erik A. Nelson, Hiroshi Ikeda, Sonia Vallet, et al. "AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity." Blood 116, no. 21 (November 19, 2010): 2994. http://dx.doi.org/10.1182/blood.v116.21.2994.2994.
Повний текст джерелаChang, Bill H., Jessica Leonard, Joelle Wolf, Michelle Degnin, Kyle Lenz, Beth Wilmot, Charles G. Mullighan, et al. "Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia." Blood 132, Supplement 1 (November 29, 2018): 4026. http://dx.doi.org/10.1182/blood-2018-99-115706.
Повний текст джерелаGriffin, Patrick, Steffan T. Nawrocki, Takashi Satou, Claudia M. Espitia, Kevin R. Kelly, Maki Hasegawa, Swaminathan Padmanabhan, Angela Romanelli, Ron de Jong, and Jennifer S. Carew. "The Investigational Multi-Targeted Kinase Inhibitor TAK-901 Antagonizes Acute Myeloid Leukemia Pathogenesis: Results of Preclinical Studies." Blood 118, no. 21 (November 18, 2011): 581. http://dx.doi.org/10.1182/blood.v118.21.581.581.
Повний текст джерелаLi, Lingxiao, Praechompoo Pongtornpipat, Soham D. Puvvada, and Jonathan H. Schatz. "Targeting MYC Expression With CDK Inhibitors Shows Potency In Preclinical Models Of High-Risk Diffuse Large B-Cell Lymphom." Blood 122, no. 21 (November 15, 2013): 1831. http://dx.doi.org/10.1182/blood.v122.21.1831.1831.
Повний текст джерелаBrummendorf, Tim H., Artur Gontarewicz, Gunhild Keller, Jürgen Moll, Melanie Braig, Imke Rohe, Edgar Jost, et al. "Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib." Blood 114, no. 22 (November 20, 2009): 1724. http://dx.doi.org/10.1182/blood.v114.22.1724.1724.
Повний текст джерелаGiles, Francis, Jorge Cortes, Donald A. Bergstrom, Alan Xiao, Penny Bristow, Dan Jones, Srdan Verstovsek, Deborah Thomas, Hagop Kantarjian, and Steven J. Freedman. "MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML)." Blood 108, no. 11 (November 16, 2006): 163. http://dx.doi.org/10.1182/blood.v108.11.163.163.
Повний текст джерелаGauler, Thomas Christoph, Benjamin Besse, Silvia Novello, Egbert F. Smit, Elizabeth R. Plummer, Jean-Pierre Delord, Maurizio Nicodemo, et al. "Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e19138-e19138. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e19138.
Повний текст джерелаShah, Pooja A., Tuhina Mazumdar, Reid T. Powell, Li Shen, Jing Wang, Clifford C. Stephen, Mitchell J. Frederick, and Faye M. Johnson. "Abstract 2847: Concurrent inactivation of PI3K and PLK1 is synergistic and overcomes acquired resistance to PI3K inhibitors in NOTCH1MUT HNSCC." Cancer Research 83, no. 7_Supplement (April 4, 2023): 2847. http://dx.doi.org/10.1158/1538-7445.am2023-2847.
Повний текст джерелаTauchi, Tetsuzo, Daigo Akahane, Kousuke Nunoda, Seiichi Okabe, John Pollard, and Kazuma Ohyashiki. "Combined Effects of a Pan-Aurora Kinase Inhibitor MK-0457 and Dasatinib Against T315I Mutant Form of BCR-ABL: In Vitro and In Vivo Studies." Blood 110, no. 11 (November 16, 2007): 805. http://dx.doi.org/10.1182/blood.v110.11.805.805.
Повний текст джерелаLawasut, Panisinee, Hannah M. Jacobs, Jake E. Delmore, Joseph Negri, Douglas W. McMillin, Ellen L. Weisberg, James D. Griffin, Paul G. Richardson, Kenneth C. Anderson, and Constantine S. Mitsiades. "In Vitro Anti-Myeloma Activity of the Multitargeted Kinase Inhibitor Midostaurin in the Context of Heterotypic Cocultures of Myeloma Cells with Nonmalignant Microenvironmental Accessory Cells." Blood 118, no. 21 (November 18, 2011): 2923. http://dx.doi.org/10.1182/blood.v118.21.2923.2923.
Повний текст джерелаCortes, Jorge, Gail J. Roboz, Hagop Kantarjian, Eric Feldman, Judy Karp, Allyson Pollack, Katrina Sandy, Niranjan Rao, Shiro Akinaga, and Mark Levis. "A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS." Blood 110, no. 11 (November 16, 2007): 909. http://dx.doi.org/10.1182/blood.v110.11.909.909.
Повний текст джерелаBagashev, Asen, Joseph Patrick Loftus, Colin Wakefield, Gerald Wertheim, Christian Hurtz, Martin P. Carroll, Kimberly Stegmaier, Yana Pikman, and Sarah K. Tasian. "Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL." Blood 138, Supplement 1 (November 5, 2021): 705. http://dx.doi.org/10.1182/blood-2021-148671.
Повний текст джерелаDelmore, Jake, David N. Cervi, Douglas McMillin, Efstathios Kastritis, Jana Jakubikova, Melissa G. Ooi, Steffen Klippel, et al. "The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies." Blood 114, no. 22 (November 20, 2009): 730. http://dx.doi.org/10.1182/blood.v114.22.730.730.
Повний текст джерелаMastrogamvraki, Natalia, and Apostolos Zaravinos. "Signatures of co-deregulated genes and their transcriptional regulators in colorectal cancer." npj Systems Biology and Applications 6, no. 1 (July 31, 2020). http://dx.doi.org/10.1038/s41540-020-00144-8.
Повний текст джерелаPatnaik, Sunil Kumar, Akey Krishna Swaroop, Mudavath Ravi Naik, Jubie Selvaraj, and Moola Joghee Nanjan Chandrasekar. "Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2." Drug Research, April 17, 2023. http://dx.doi.org/10.1055/a-2030-4078.
Повний текст джерела